Adaptive COVID-19 Treatment Trial 1
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:abbreviation |
gptkb:ACTT-1
|
| gptkbp:clinicalTrials.govID |
gptkb:NCT04280705
|
| gptkbp:conditionStudied |
gptkb:COVID-19
|
| gptkbp:conductedBy |
gptkb:National_Institute_of_Allergy_and_Infectious_Diseases
|
| https://www.w3.org/2000/01/rdf-schema#label |
Adaptive COVID-19 Treatment Trial 1
|
| gptkbp:location |
gptkb:Asia
gptkb:Europe gptkb:Japan gptkb:Mexico gptkb:United_States |
| gptkbp:participants |
1062
|
| gptkbp:period |
Phase 3
|
| gptkbp:principalInvestigator |
John H. Beigel
|
| gptkbp:publicationDate |
October 8, 2020
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
time to recovery
remdesivir shortened recovery time compared to placebo |
| gptkbp:startDate |
February 2020
|
| gptkbp:studiedDrug |
gptkb:remdesivir
placebo |
| gptkbp:bfsParent |
gptkb:ACTT-1
|
| gptkbp:bfsLayer |
6
|